FDA Expands Authorization Around Remdesivir to Treat COVID-19

January 25, 2022

On January 21, the FDA expanded the use of remdesivir to non-hospitalized adults and children who have mild-to-moderate COVID-19, who are at risk of severe disease. Previously, remdesivir was only available to hospitalized patients. Remdesivir is administered via intravenous infusion over a three day period, and doses will be adjusted for pediatric patients depending on their weight. “Given the similar course of COVID-19 disease, the authorization of [remdesivir] in certain pediatric patients is based on extrapolation of efficacy from adequate and well-controlled studies in adults.”

This decision was based on a clinical trial including 562 participants with mild-to-moderate COVID-19, who had displayed symptoms within the previous 7 days and had at least one risk factor for severe disease. 279 patients were given at least one dose of remdesivir, and 283 were given a placebo. “A total of 4 of 246 patients (1.6%) in the remdesivir group and 21 of 252 (8.3%) in the placebo group had a Covid-19–related medically attended visit by day 28. No patients had died by day 28. Adverse events occurred in 42.3% of the patients in the remdesivir group and in 46.3% of those in the placebo group.” Laboratory tests have shown that remdesivir is effective at neutralizing the Omicron variant.

Gilead, who owns remdesivir, has recently started a Phase 1 clinical trial for a remdesivir pill to combat COVID-19.





Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.

By adding your phone number, you agree to receive text message updates. Msg & data rates may apply.